Verification of monoclonal antibody (mAb) purity detection methods is a key link to ensure drug quality. However, in the current validation practice of size exclusion high-performance liquid chromatography (SEC-HPLC) and capillary electrophoresis (CE), there are outstanding problems such as inconsistent technical implementation and "formalization" of projects, and there are many disputes over the selection of validation projects. Among them, the SEC-HPLC area normalization method is the most widely used semi-quantitative analysis method for polymers in enterprises. The selection and implementation of verification projects are particularly chaotic. At the same time, methods such as ion exchange chromatography (IEC) often fail to achieve baseline separation, and their verification logic has also become the focus of the industry. This article is based on the 2025 version of the Pharmacopoeia of the People's Republic of China (ChP 2025), the latest specifications of the United States Pharmacopoeia (USP) and the results of special literature research, systematically sorting out the chaos and core disputes in enterprise verification, focusing on interpreting the verification project design logic of the SEC-HPLC area normalization method, explaining the core reasons for choosing this method for purity testing of biological products, and focusing on IEC that does not reach baseline separation. The testing method proposes verification ideas, starting from the perspective of method characteristics, pharmacopoeia requirements, and risk control, and summarizes a unified verification plan design idea to provide enterprises with a technical reference that is both compliance and practical, and promote the standardized development of industry verification practices.